Business, energy, technology, markets and global industry news from Business News Today

relabotulinumtoxinA

Pharma & Biotech

Galderma wins China approval for Relfydess, but can its six-month wrinkle treatment challenge established Botox rivals?

Galderma wins China approval for Relfydess after positive Phase 3 frown line results. Competition and its pending US review remain crucial.

Read More
Pharma & Biotech

Galderma’s relabotulinumtoxinA FDA setback shifts attention to manufacturing readiness

Discover why FDA manufacturing concerns have delayed Galderma’s relabotulinumtoxinA approval and what the company must resolve next.

Read More